Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.
Also called NCT06055452
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 120 participants
- Registry
-
NCT06055452
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06055452. Randomized; quadruple masking; primary purpose prevention. Start 2024-01-19 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
- Condition
- Pre-Heart Failure
- Condition
- Hypertension
- Intervention (Drug)
- Empagliflozin 10 MG
- Intervention (Drug)
- Placebo
- Lead sponsor
- China National Center for Cardiovascular Diseases
Record details
- Record id
cardio:ct-nct06055452- Content hash
19e62c70355c3b9c0945a344bd906019f581e74a440a845370d84c7446fdd7c7